IndraLab
Statements
OTUD6B activates Pulmonary Arterial Hypertension. 4 / 4
|
4
reach
"The knock-down effect of siOtud6b#1 is stronger than siOtud6b#2 and siOtud6b#3.To test whether the reduction of Otud6b inhibits PAH development, we targeted Otud6b (siOtud6b, GGGAATGAAGAACGCCGTT) and non-targeted control (siNC) modified anti-siRNA oligonucleotides by trachea infusion for 3 weeks."